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Abstract
Objective To systematically review evidence regarding ataxia treatment.
Methods
A comprehensive systematic review was performed according to American Academy of Neurology methodology.
Conclusions
For patients with episodic ataxia type 2, 4-aminopyridine 15 mg/d probably reduces ataxia attack frequency over 3 months (1 Class I study). For patients with ataxia of mixed etiology, riluzole probably improves ataxia signs at 8 weeks (1 Class I study). For patients with Friedreich ataxia or spinocerebellar ataxia (SCA), riluzole probably improves ataxia signs at 12 months (1 Class I study). For patients with SCA type 3, valproic acid 1,200 mg/d possibly improves ataxia at 12 weeks. For patients with spinocerebellar degeneration, thyrotropin-releasing hormone possibly improves some ataxia signs over 10 to 14 days (1 Class II study). For patients with SCA type 3 who are ambulatory, lithium probably does not improve signs of ataxia over 48 weeks (1 Class I study). For patients with Friedreich ataxia, deferiprone possibly worsens ataxia signs over 6 months (1 Class II study). Data are insufficient to support or refute the use of numerous agents. For nonpharmacologic options, in patients with degenerative ataxias, 4-week inpatient rehabilitation probably improves ataxia and function (1 Class I study); transcranial magnetic stimulation possibly improves cerebellar motor signs at 21 days (1 Class II study). For patients with multiple sclerosis-associated ataxia, the addition of pressure splints possibly has no additional benefit compared with neuromuscular rehabilitation alone (1 Class II study). Data are insufficient to support or refute use of stochastic whole-body vibration therapy (1 Class III study).
The cerebellum is composed of the vermis, the hemispheres, and 3 cerebellar peduncles on each side, and contributes largely to balance and motor coordination. The causes of cerebellar dysfunction are numerous and include vitamin deficiencies, structural lesions (caused by tumors or trauma), infection, inflammation, toxins, neurodegeneration, genetics, stroke, multiple sclerosis (MS), and metabolic disorders. Motor signs resulting from cerebellar dysfunction may include some or all of the following: imbalance, impaired coordination, limb and body tremor, dysarthria, and oculomotor abnormalities. Other neurologic symptoms and signs may accompany cerebellar dysfunction, including dystonia, muscle weakness, oculomotor abnormalities, neuropathy, parkinsonism, spasticity, impaired visual acuity, and sensory impairment; these symptoms and signs are beyond the scope of this review. Mood, cognitive disorders, and autonomic dysfunction may also occur. Ataxia may result from cerebellar or sensory impairment.
There is currently no approved therapy to treat cerebellar motor dysfunction, and no pharmacologic or surgical treatment is routinely used. Various therapies have been studied in clinical trials for the past 40 years, although no consensus has been reached on their effectiveness. This comprehensive systematic review synthesizes the literature on the treatment of cerebellar motor dysfunction to answer the following questions:
1. For patients with cerebellar motor dysfunction, do pharmacologic therapies, compared with no (or alternative) treatments, improve motor symptoms with acceptable safety and tolerability? 2. For patients with cerebellar motor dysfunction, do surgical or other interventional therapies (e.g., physical training), compared with no (or alternative) treatments, improve motor symptoms with acceptable safety and tolerability? 3. For patients with cerebellar motor dysfunction, does transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS), compared with no (or alternative) treatments, improve motor symptoms with acceptable safety and tolerability?
This article summarizes the systematic review findings and conclusions. Full text of the systematic review is available as a data supplement at http://npub.org/0t5ncn.
Description of the analytic process
This project used a hybrid of American Academy of Neurology (AAN) systematic review methodologic processes; the development panel used the AAN's 2004 process manual 1 for the overall approach but held a public comment period and applied the updated classification of evidence scheme for therapeutic studies that had been approved and then published as an amendment to the 2011 manual.
2 A description of the exact methodology followed, including the convening of the author panel, literature search strategy, and the process for reviewing evidence, is available in the full-length review. Articles authored by individuals participating in the systematic review were assessed by nonconflicted panel members. Conflicts of interest were assessed and judged to be balanced when the comprehensive systematic review was initiated and again at its conclusion. Although new conflicts appeared during the multiyear process, at least half of the panel was without conflict throughout the entirety of the process. Studies without an independent control group are considered Class IV under the updated classification of evidence scheme. Because many studies predate the determination of genotypes causing cerebellar motor dysfunction, the development panel retained the nosology used by the authors of each article. As the pathophysiology and neurochemistry of the ataxias may vary between types, the different diagnoses were considered separately wherever possible. Adverse events are discussed in the full-length review. Glossary AAN = American Academy of Neurology; CI = confidence interval; EA2 = episodic ataxia type 2; FA = Friedreich ataxia; FARS = Friedreich Ataxia Rating Scale; ICARS = International Cooperative Ataxia Rating Scale; MS = multiple sclerosis; NESSCA = Neurological Examination Score for Spinocerebellar Ataxia; OR = odds ratio; SARA = Scale for the Assessment and Rating of Ataxia; SCA = spinocerebellar ataxia; SCA3 = spinocerebellar ataxia type 3; SCD = spinocerebellar degeneration; tDCS = transcranial direct current stimulation; TMS = transcranial magnetic stimulation; TRH = thyrotropin-releasing hormone; VPA = valproic acid.
Analysis of evidence
After 3 months of treatment, the median monthly attack frequency was 1.65 (interquartile range 1.00-4.78) compared with a median monthly attack frequency of 6.50 (interquartile range 2.33-13.75) with placebo (p = 0.03).
4-Aminopyridine conclusion
For patients with EA2, 4-aminopyridine 15 mg/d probably reduces the frequency of ataxia attacks over a 3-month period (1 Class I study).
Riluzole
Forty patients with ataxia of mixed etiology were administered riluzole 100 mg/d in a randomized, double-blind, placebocontrolled, single-center Class I study. 4 A follow-up, randomized, double-blind, placebo-controlled, Class I study investigated the benefit of riluzole 50 mg twice daily for 12 months in 60 patients with spinocerebellar ataxia (SCA) or Friedreich ataxia (FA). 5 The primary endpoint was the proportion of patients with an improved Scale for the Assessment and Rating of Ataxia (SARA) score at 12 months, which was better in the riluzole group (OR 8.00, 95% CI 1.95-32.83), including after a post hoc logistic regression analysis adjusting for sex, age, and ataxia type (OR 9.76, 95% CI 2.08-45.80), in the 55 patients who received treatment. Mean difference in change in SARA score was also better in the riluzole group (−1.50, 95% CI −2.59 to −0.40, at 3 months; −2.68, 95% CI −3.98 to −1.39, at 12 months).
Riluzole conclusion
For patients with ataxia of various etiologies, riluzole 100 mg/ d is probably effective for short-term treatment as measured by the ICARS at 8 weeks (1 Class I study). In patients with SCA or FA, riluzole 100 mg/d is probably effective for improving ataxia as measured by the SARA at 12 months (1 Class I study). Patients receiving riluzole require monitoring of liver enzymes.
Weak evidence Valproic acid
In a Class II, randomized, double-blind, placebo-controlled study, 6 patients with SCA type 3 (SCA3)/Machado-Joseph disease were randomized to receive high-dose valproic acid (VPA) (1,200 mg/d), low-dose VPA (800 mg/d), or placebo for 12 weeks. Mean change in SARA total score over 12 weeks was significantly greater in the 1,200-mg/d group (−2.05) compared with both the 800-mg/d (−1.58) and placebo (−0.75) groups (analysis of variance p = 0.021). The clinical importance of this difference in mean change is uncertain.
VPA conclusion
For patients with SCA3, VPA 1,200 mg/d is possibly effective for improving SARA total score at 12 weeks (1 Class II study).
Thyrotropin-releasing hormone
A randomized, double-blind, placebo-controlled, Class II study (predating genetic testing) of 254 patients with "spinocerebellar degeneration" (SCD) administered 0.5 and 2 mg of thyrotropin-releasing hormone (TRH), intramuscularly, once daily for 2 weeks. 7 A higher percentage of patients with late-onset cerebellar cortical atrophy and olivopontocerebellar atrophy were rated as "markedly improved" or "moderately improved" at 2 weeks when treated with TRH compared with placebo (p < 0.05, exact value not reported). In the overall group, more patients treated with TRH had a higher "improvement ratio" for the signs of dysarthria, standing, and gait disorder (p < 0.05, exact value not reported). The article focused only on signs that improved. The clinical significance of these change scores is unknown.
TRH conclusion
For patients with SCD, TRH use possibly improves some signs of ataxia over 10 to 14 days (1 Class II study). The clinical significance of these changes is uncertain.
Medications with evidence against benefit
Moderate evidence Lithium carbonate A double-blind, randomized, placebo-controlled, Class I study evaluated lithium carbonate (dosed to serum target levels of 0.5-0.8 mEq/L) in 62 patients with SCA3 who were ambulatory. 8 After 48 weeks of treatment, no difference was seen in mean scores on the primary endpoint, the Neurological Examination Score for Spinocerebellar Ataxia (NESSCA), as assessed by a generalized estimation equation using baseline measurements as covariates (NESSCA total score −0.38 points in the lithium group vs placebo, 95% CI −1.7 to 1.0). No difference was observed on the SARA total score (a secondary outcome) at 48 weeks (lithium effect vs placebo −0.96, 95% CI −2.38 to 0.46). Small but statistically significant changes were noted in certain secondary outcome measures when those receiving lithium were compared with the placebo group; the clinical relevance of these scales is not established. In further analysis, 9 the treatment group had less worsening on the cerebellar NESSCA (range: 0-7 points) at 24 weeks (−0.81, 95% CI −1.18 to −0.44) and 48 weeks (−0.64, 95% CI −1.05 to −0.23).
Lithium carbonate conclusion
For patients with SCA3 who are ambulatory, lithium probably does not improve ataxia over 48 weeks as measured by the NESSCA and SARA total scores (1 Class I study), although minimal clinically important differences on these scales have not been established and small changes cannot be excluded.
Weak evidence Deferiprone
A Class II study described the administration of deferiprone (20, 40 , and 60 mg/kg/d divided in 2 doses) over 6 months to 72 patients with FA who were ambulatory. 10 The 60-mg/kg/ d group was discontinued because of perceived/observed worsening of ataxia. Patients receiving 40 mg/d experienced significant worsening of ataxia compared with the placebo group, as measured by the Friedreich Ataxia Rating Scale (FARS) total score (difference in mean change 5.4, 95% CI 1.5-9.3) and the ICARS total score (difference in mean change 4.7, 95% CI 0.5-8.9). There were no significant differences between the group treated with 20 mg/kg/d and the placebo group (difference in FARS total score mean change −0.3, 95% CI −3.8 to 3.2; difference in ICARS total score mean change −0.6, 95% CI −4.5 to 3.3).
Deferiprone conclusion
For patients with FA, deferiprone 40 mg/kg/d possibly worsens ataxia signs over 6 months (1 Class II study).
Medications with conflicting results or insufficient evidence
Pharmacologic therapies for which no conclusions for or against use could be drawn are described in the table, with details provided in the full-length review. The idebenone literature is described briefly here because this treatment has been the subject of 3 randomized controlled trials. In the first study, 11 there was no difference in ICARS change scores at 6 months by analysis of covariance (p = 0.17), but the intermediate-and highdose groups had a greater mean change on the ICARS compared with the placebo group (difference in change vs placebo: low-dose 5 mg/kg −1.99 [95% CI −7.54 to 3.57], Bonferroniadjusted p = 1.00; intermediate-dose 15 mg/kg −6.24 [95% CI −10.89 to −1.60], Bonferroni-adjusted p = 0.03; high-dose 45 mg/kg −7.76 [95% CI −12.56 to −2.96], Bonferroni-adjusted p = 0.010); the difference in mean change on the FARS between the treatment and control groups was not significant, but the CIs included the possibility of clinically important effects. The second study found no difference in improvement on the ICARS scores between groups, but did not have sufficient precision to exclude a clinically important effect. 12 A random-effects metaanalysis of these 2 studies showed a greater mean change on the ICARS in the idebenone group, but with CIs that included the possibility of no effect (difference in mean score change −4.2, 95% CI −9.0 to 0.7, I 2 = 38%). When data for the 45-mg/kg group in the first study were combined with those for the 30-to 54-mg/kg group in the second study, the difference in mean score change between idebenone and placebo was −4.5 (95% CI −11.0 to 2.0, I 2 = 71%).
A third double-blind, placebo-controlled trial investigating idebenone for use in FA ended in 2010, but it could not be included, as it is unpublished and available data are insufficient for classification of evidence and analysis. According to a press release, 13 there was no difference in the mean change in ICARS score from baseline between the active arms and placebo, and a meta-analysis of the manufacturer's 3 studies showed no statistically significant mean change in ICARS scores between groups.
Because of these different findings, the lack of statistical precision, and the inability to incorporate a large unpublished randomized controlled trial, no conclusions could be drawn for or against idebenone use (table).
The
Pressure splints A Class II study of patients with MS-associated ataxia randomized patients to receive neuromuscular rehabilitation only (control group, n = 13) or neuromuscular rehabilitation plus pressure splints (treatment group, n = 13) 3 times weekly for 4 weeks. 14 No posttreatment differences were noted between groups for most gait parameters/equilibrium tests. Data were insufficient to calculate 95% CIs for between-group change scores.
Pressure splints conclusion
For patients with MS-associated ataxia, the addition of pressure splints to neuromuscular rehabilitation possibly has no additional benefit over neuromuscular rehabilitation alone (1 Class II study).
Physical and occupational therapy
Various therapy approaches have been evaluated to improve symptoms of ataxia; most studies in this area are rated Class IV. In a single Class I study, daily inpatient physical and occupational therapy for 4 weeks was compared with a wait-list control. 15 At 4 weeks, patients with SCA type 6, SCA type 31, and idiopathic cerebellar ataxia receiving rehabilitation had a greater reduction in the SARA total score (mean difference −3.0, 95% CI −4.3 to −1.8) and a small but significant improvement in the Functional Independence Measure total score (mean difference 1.3, 95% CI 0.4-2.0).
Physical and occupational therapy conclusion
Four-week inpatient rehabilitation in patients with isolated degenerative ataxias probably improves ataxia and functional abilities as measured at 4 weeks (1 Class I study).
Stochastic vibration therapy
There is insufficient information to support or refute the use of stochastic whole-body vibration therapy in patients with SCAs (1 Class III study). 16 Question 3: For patients with cerebellar dysfunction, does TMS or tDCS, compared with no (or alternative) treatments, improve motor symptoms with acceptable safety and tolerability? A double-blind, Class II study compared 21 daily TMS treatments over the cerebellum with sham treatments in 74 patients with various ataxias. 17 The patients treated with TMS had a greater reduction in timed 10-m walk (−1.1 seconds, estimated 95% CI −2.3 to −0.005) and 10-m steps (−1.7, estimated 95% CI −3.4 to −0.007), and a greater improvement in the number of tandem steps (1.0, estimated 95% CI 0.3-1.7) and standing capacity (as assessed on a 0-to 6-point scale with lower scores indicating better function (−0.32, estimated 95% CI −0.6 to −0.001). The clinical significance of these differences is uncertain.
A Class III, randomized, double-blind, crossover study 18 compared a single session of anodal cerebellar tDCS with sham stimulation separated by at least 1 week in 19 patients with various ataxias. The SARA score was better after tDCS 19 Assadi 2007 20 There is insufficient evidence to support or refute a benefit of buspirone for treatment of cerebellar motor dysfunction because of conflicting Class III studies.
L-Tryptophan
Trouillas 1988, 21 Wessel 1995 22 There is insufficient evidence to support or refute a benefit of L-tryptophan for treatment of cerebellar motor dysfunction because of conflicting Class III studies with limited available data.
Choline
Sehested 1980, 23 Austin 1984, 24 Lawrence 1980, 25 Livingstone 1981 26 There is insufficient evidence to support or refute a benefit of choline for treatment of ataxia because of conflicting Class III studies with limited available data.
Varenicline
Zesiewicz 2012 27 For patients with SCA3, there is insufficient evidence to support or refute whether varenicline (mean dose of 1.67 mg/d) is effective in treating ataxia over 4 weeks, as measured by the SARA total score (1 Class II study with insufficient precision for the primary outcome measure).
Ondansetron
Bier 2003, 28 Mandelcorn 2004, 29 Rice 1997 30 There is insufficient evidence to support or refute a benefit of ondansetron for patients with ataxia (1 Class II study with insufficient precision, 1 Class III study with no statistics/insufficient precision, and 1 Class III cerebellar tremor study with only 2 assessable patients with cerebellar degeneration).
Dolasetron mesylate

Monaca-Charley 2003 31
There is insufficient evidence to support or refute a benefit of dolasetron mesylate for patients with a cerebellar syndrome secondary to MS (1 Class III study).
Trimethoprimsulfamethoxazole
Schulte 2001 32 There is insufficient evidence to support or refute a benefit of trimethoprimsulfamethoxazole for patients with SCA3 (1 Class III study).
Zinc
Velazquez-Perez 2011 33 There is insufficient evidence to support or refute a benefit of zinc for patients with SCA2 (1 Class II study with limited precision).
L-Carnitine
Sorbi 2000 34 There is insufficient evidence to support or refute a benefit of L-carnitine for patients with degenerative cerebellar ataxia (1 Class III study).
Physostigmine
Kark 1981, 35 Wessel 1997 36 There is insufficient evidence to support or refute a benefit of physostigmine for patients with cerebellar ataxia (2 Class III studies over different time periods and with limited descriptions of results).
Amantadine
Botez 1996 37
There is insufficient evidence to support or refute a benefit of amantadine for patients with cerebellar ataxia (1 Class III study).
Branched-chain amino acids
Mori 2002 38 There is insufficient evidence to support or refute a benefit of branched-chain amino acids for patients with cerebellar ataxia (1 Class III study).
Betamethasone
Zannolli 2012 39 There is insufficient evidence to support or refute a benefit of betamethasone for patients with ataxia-telangiectasia (1 Class III study).
Abbreviations: FA = Friedreich ataxia; MS = multiple sclerosis; RCT = randomized controlled trial; SARA = Scale for the Assessment and Rating of Ataxia; SCA2 = spinocerebellar ataxia type 2; SCA3 = spinocerebellar ataxia type 3. The references cited here can be found in the full-length guideline, available online as a data supplement at http://npub.org/0t5ncn. treatment vs sham (mean difference 1.40, 95% CI 0.94-1.85), as was the ICARS (mean difference 4.37, 95% CI 3.27-5.47).
Conclusion
TMS over the cerebellum possibly improves cerebellar motor function at 21 days in patients with SCD and olivopontocerebellar atrophy (1 Class II study). There is insufficient evidence to support or refute use of a single session of anodal cerebellar tDCS for the treatment of ataxia (1 Class III study).
Discussion and suggestions for future research
Although studies of populations with rare diseases are challenging, rigorous study design is critical to assess the outcomes associated with new therapeutic options. This is true for both pharmacologic and nonpharmacologic studies. In addition to the studies described here, numerous Class IV studies were identified in the literature search. Under the 2011 AAN process, as amended, masked pretreatment and posttreatment study designs are insufficient to achieve Class III status. 2 Only 2 rehabilitation studies were identified with a classification better than Class IV, and yet in practice, many clinicians find it helpful to refer patients with ataxia for therapy to help with daily function if not the ataxia itself. This review focused specifically on treatment of cerebellar motor dysfunction and ataxia; many of these conditions have associated signs and symptoms both within and outside the neurologic system that could potentially benefit from therapies not covered in this review. Dietary changes, including the use of a gluten-free diet to treat ataxia, were outside the scope of this systematic review. In addition, historical treatment approaches, such as the use of acetazolamide for the treatment of EA2, can have clinical value even in the absence of clinical trial evidence.
Future research in cerebellar motor dysfunction should analyze and document specific causes (genotype); define groups of diseases according to their mechanism of action (e.g., gain vs loss of function, toxicity); and utilize more precise outcome measures, including clinical and functional rating scales. More specific and potent candidate drugs for both symptomatic and disease-modifying studies are needed, as well as more sensitive clinical measures and biomarkers. Moreover, long-term studies to detect disease-modifying potential beyond symptomatic treatment should be conducted. Finally, the clinical trials must be adequately powered to detect a meaningful difference for each etiology.
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